The FDA on February 15, 2024, granted traditional approval to TEPMETKO® for adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) harboring Mesenchymal-Epithelial Transition (MET) exon 14 skipping alterations. TEPMETKO® is a product of EMD Serono, Inc.
Bottom Ad
Advertisement
Subscribe
